Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals

被引:26
|
作者
Tamaki, Nobuharu [1 ,2 ]
Higuchi, Mayu [1 ]
Kurosaki, Masayuki [1 ]
Kirino, Sakura [1 ]
Osawa, Leona [1 ]
Watakabe, Keiya [1 ]
Wang, Wan [1 ]
Okada, Mao [1 ]
Shimizu, Takao [1 ]
Takaura, Kenta [1 ]
Takada, Hitomi [1 ,2 ]
Kaneko, Shun [1 ]
Yasui, Yutaka [1 ]
Tsuchiya, Kaoru [1 ]
Nakanishi, Hiroyuki [1 ]
Itakura, Jun [1 ]
Takahashi, Yuka [1 ]
Enomoto, Nobuyuki [2 ]
Izumi, Namiki [1 ]
机构
[1] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, 1-26-1 Kyonan Cho, Musashino, Tokyo 1808610, Japan
[2] Univ Yamanashi, Fac Med, Dept Internal Med 1, Chuo Ku, Kofu, Yamanashi, Japan
关键词
chronic hepatitis C; FIB-4; hepatocellular carcinoma; magnetic resonance elastography; Wisteria floribunda agglutinin-positive mac-2 binding protein; MR ELASTOGRAPHY; LIVER FIBROSIS; LI-RADS; THERAPY; PREDICTOR; DIAGNOSIS; IMPACT;
D O I
10.1111/jvh.13103
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Prediction of hepatocellular carcinoma (HCC) development after sustained virological response (SVR) is clinically important, and the usefulness of noninvasive markers for prediction HCC have been reported. The aim of this study was to compare the prediction accuracy for HCC development by noninvasive markers. A total of 346 patients with chronic hepatitis C without history of HCC who achieved SVR through direct-acting antivirals were included. Magnetic resonance elastography (MRE) and serum fibrosis markers were measured 12 weeks after the end of treatment, and the subsequent HCC development was examined. The mean observation period was 26.4 +/- 7.9 months, and 24 patients developed HCC. Area under the receiver operating characteristic curve of liver stiffness by MRE, Wisteria floribunda agglutinin-positive mac-2 binding protein and FIB-4 for predicting HCC within 3 years was 0.743, 0.697 and 0.647, respectively. The 1/2/3-year rates of HCC development in patients with liver stiffness >= 3.75 KPa were 6.6%, 11.9% and 14.5%, whereas they were 1.4%, 2.5% and 2.5% in patients with liver stiffness KPa (P < 0.001). Multivariate analysis revealed that liver stiffness >= 3.75 was an independent predictive factor for HCC development (hazard ratio, 3.51; 95% confidence interval, 1.24-9.99). In subgroup analysis, there were 132 patients who were KPa, and no HCC development was observed in these patients. Diagnostic accuracy for predicting HCC development was higher in MRE than serum fibrosis markers and measurement of liver stiffness by MRE could identify patients with high and low risk of HCC development after SVR.
引用
收藏
页码:893 / 899
页数:7
相关论文
共 50 条
  • [31] Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response
    Tada, Toshifumi
    Nishimura, Takashi
    Matono, Tomomitsu
    Yoshida, Masahiro
    Yuri, Minako
    Fujiwara, Aoi
    Yuri, Yukihisa
    Takashima, Tomoyuki
    Aizawa, Nobuhiro
    Ikeda, Naoto
    Enomoto, Hirayuki
    Kumada, Takashi
    Iijima, Hiroko
    HEPATOLOGY RESEARCH, 2021, 51 (08) : 860 - 869
  • [32] Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy
    Tokita, H
    Fukui, H
    Tanaka, A
    Kamitsukasa, H
    Yagura, M
    Harada, H
    Okamoto, H
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 (05) : 752 - 758
  • [33] Changes of liver stiffness measured by magnetic resonance elastography during direct-acting antivirals treatment in patients with chronic hepatitis C
    Higuchi, Mayu
    Tamaki, Nobuharu
    Kurosaki, Masayuki
    Inada, Kento
    Kirino, Sakura
    Yamashita, Koji
    Hayakawa, Yuka
    Sekiguchi, Shuhei
    Osawa, Leona
    Takaura, Kenta
    Maeyashiki, Chiaki
    Kaneko, Shun
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Nakanishi, Hiroyuki
    Itakura, Jun
    Enomoto, Nobuyuki
    Izumi, Namiki
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (06) : 3744 - 3751
  • [34] Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence
    Musa, Nevine Ibrahim
    Mohamed, Inas Elkhedr
    Abohalima, Ahmed Samir
    EGYPTIAN LIVER JOURNAL, 2020, 10 (01)
  • [35] Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence
    Nevine Ibrahim Musa
    Inas Elkhedr Mohamed
    Ahmed Samir Abohalima
    Egyptian Liver Journal, 10 (1)
  • [36] Risk of hepatocellular carcinoma in patients with chronic hepatitis C and stage-3 liver fibrosis after sustained virological response with direct acting antivirals
    Sanchez-Azofra, Maria
    Fernandez Vazquez, Inmaculada
    Luisa Garcia, Maria
    Dominguez, Lourdes
    Fernandez-Rodriguez, Conrado
    Bonet, Lucia
    Montes, Marisa
    Ryan, Pablo
    Gea, Francisco
    Diaz Sanchez, Antonio
    Garcia-Mayor, Marian
    Luisa Manzano, Maria
    Gonzalez Moreno, Leticia
    Bisbal, Otilia
    Martin Carbonero, Luz
    Luisa Gutierrez, Maria
    Guerrero Garcia, Antonio
    Rivero, Miguel
    Elena Portales, Maria
    Olveira Martin, Antonio
    Castillo, Pilar
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E731 - E731
  • [37] The effect of sustained virological response by direct-acting antivirals on insulin resistance and diabetes mellitus in patients with chronic hepatitis C
    Adinolfi, Luigi Elio
    Rinaldi, Luca
    Marrone, Aldo
    Giordano, Mauro
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2018, 16 (08) : 595 - 597
  • [38] The impact of achieving a sustained virological response with direct-acting antivirals on serum autotaxin levels in chronic hepatitis C patients
    Shereen Abou Bakr Saleh
    Khaled Mohamed Abdelwahab
    Asmaa Mady Mady
    Ghada Abdelrahman Mohamed
    Egyptian Liver Journal, 10 (1)
  • [39] The impact of achieving a sustained virological response with direct-acting antivirals on serum autotaxin levels in chronic hepatitis C patients
    Saleh, Shereen Abou Bakr
    Abdelwahab, Khaled Mohamed
    Mady, Asmaa Mady
    Mohamed, Ghada Abdelrahman
    EGYPTIAN LIVER JOURNAL, 2020, 10 (01)
  • [40] Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients
    Ma, Longteng
    Liu, Jiluo
    Wang, Wei
    Yang, Fan
    Li, Ping
    Cai, Shiliang
    Zhou, Xinyu
    Chen, Xi
    Zhuang, Xun
    Zhang, Hongwei
    Cao, Guangwen
    FUTURE ONCOLOGY, 2020, 16 (11) : 675 - 686